[Clinical experience with FK 506]
- PMID: 1722311
[Clinical experience with FK 506]
Abstract
FK 506 is a superior immunosuppressive agent that should improve patient survival after the commonly performed transplant procedures, make feasible transplantations that have been previously impractical, allow immune intervention for serious autoimmune diseases, and create a better spin-off understanding of basic biologic processes including signal transduction.
Similar articles
-
FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.Springer Semin Immunopathol. 1993;14(4):323-44. doi: 10.1007/BF00192307. Springer Semin Immunopathol. 1993. PMID: 7686690 Free PMC article. Review. No abstract available.
-
Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.Clin Transplant. 1997 Aug;11(4):299-312. Clin Transplant. 1997. PMID: 9267719 Clinical Trial.
-
Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.Bone Marrow Transplant. 2000 Nov;26(9):985-91. doi: 10.1038/sj.bmt.1702639. Bone Marrow Transplant. 2000. PMID: 11100278
-
Retinal complications in patients with solid organ or bone marrow transplantations.Transplantation. 2007 Mar 27;83(6):694-9. doi: 10.1097/01.tp.0000259386.59375.8a. Transplantation. 2007. PMID: 17414700
-
Tacrolimus in the treatment of idiopathic nephrotic syndrome.Expert Opin Investig Drugs. 2007 Jul;16(7):1099-110. doi: 10.1517/13543784.16.7.1099. Expert Opin Investig Drugs. 2007. PMID: 17594193 Review.
Cited by
-
Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases.Transplant Proc. 1991 Dec;23(6):3325-7. Transplant Proc. 1991. PMID: 1721450 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical